International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting
Phase of Trial: Phase IV
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Adverse reactions; Therapeutic Use
- Acronyms SENTINEL study
- Sponsors Novartis Pharmaceuticals
- 11 Jan 2017 New trial record
- 06 Dec 2016 Results assessing safety presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results assessing treatment outcomes presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.